Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Daprodustat by GSK for Anemia in Chronic Kidney Disease (Renal Anemia): Likelihood of Approval
Daprodustat is under clinical development by GSK and currently in Phase III for Anemia in Chronic Kidney Disease (Renal Anemia)....
Momelotinib dihydrochloride by GSK for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis): Likelihood of Approval
Momelotinib dihydrochloride is under clinical development by GSK and currently in Phase III for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis). According...
Belantamab mafodotin by GSK for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Phase II for Multiple Myeloma (Kahler Disease). According to...
Dostarlimab by GSK for Cervical Cancer: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of GSK's GSK-3943104A?
GSK-3943104A is a subunit vaccine commercialized by GSK, with a leading Phase II program in Genital Herpes. According to Globaldata,...
GSK-4172239D by GSK for Sickle Cell Disease: Likelihood of Approval
GSK-4172239D is under clinical development by GSK and currently in Phase I for Sickle Cell Disease. According to GlobalData, Phase...
GSK-3858279 by GSK for Osteoarthritis Pain: Likelihood of Approval
GSK-3858279 is under clinical development by GSK and currently in Phase II for Osteoarthritis Pain. According to GlobalData, Phase II...
GSK-3858279 by GSK for Diabetic Neuropathic Pain: Likelihood of Approval
GSK-3858279 is under clinical development by GSK and currently in Phase II for Diabetic Neuropathic Pain. According to GlobalData, Phase...
Meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine by GSK for Neisseria meningitidis Infections: Likelihood of Approval
Meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine is under clinical development by GSK and currently in Pre-Registration for...
GSK-3888550A by GSK for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
GSK-3888550A is under clinical development by GSK and currently in Phase III for Respiratory Syncytial Virus (RSV) Infections. According to...
GSK-3943104A by GSK for Genital Herpes: Likelihood of Approval
GSK-3943104A is under clinical development by GSK and currently in Phase II for Genital Herpes. According to GlobalData, Phase II...
GSK-324332A by GSK for Herpes Zoster (Shingles): Likelihood of Approval
GSK-324332A is under clinical development by GSK and currently in Phase III for Herpes Zoster (Shingles). According to GlobalData, Phase...
GSK-3772701 by GSK for Malaria: Likelihood of Approval
GSK-3772701 is under clinical development by GSK and currently in Phase I for Malaria. According to GlobalData, Phase I drugs...
Belimumab by GSK for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Belimumab is under clinical development by GSK and currently in Phase III for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase...
Feladilimab by GSK for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Feladilimab is under clinical development by GSK and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC). According to...
Risk adjusted net present value: What is the current valuation of GSK's LiProSal?
LiProSal is a small molecule commercialized by GSK, with a leading Phase II program in Dementia Associated With Alzheimer's Disease....
Risk adjusted net present value: What is the current valuation of GSK's Linerixibat?
Linerixibat is a small molecule commercialized by GSK, with a leading Phase III program in Pruritus. According to Globaldata, it...
Risk adjusted net present value: What is the current valuation of GSK's Cobolimab?
Cobolimab is a monoclonal antibody commercialized by GSK, with a leading Phase III program in Non-Small Cell Lung Carcinoma;Squamous Non-Small...
Risk adjusted net present value: What is the current valuation of GSK's GSK-4178116A?
GSK-4178116A is a live attenuated vaccine commercialized by GSK, with a leading Phase II program in Chicken Pox. According to...
WVE-006 by GSK for Alpha-1 Antitrypsin Deficiency (A1AD): Likelihood of Approval
WVE-006 is under clinical development by GSK and currently in Phase II for Alpha-1 Antitrypsin Deficiency (A1AD). According to GlobalData,...